Romosozumab scFv-Transferrin Fusion for Barrier-Penetrating Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells due to their size and lack of specific targeting mechanisms, limiting their therapeutic efficacy and application.

Innovation Solution

A single-chain variable fragment (scFv) is designed to bind with the N-methyl lobe of transferrin, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake, and incorporating cleavable linkers that respond to specific cellular environments for targeted and controlled release of the therapeutic agent.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a whole antibody is used for therapeutic treatment, then immune effector functions and half-life are improved, but penetration through biological barriers and cellular uptake are reduced

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidmolecular size

Core Design Contradiction:

ReliabilityVSLength of moving object

Solution Approach 1:

The antibody is segmented into its functional components: the scFv (single-chain variable fragment) retains antigen-binding capability while the Fc region is removed. This segmentation allows the therapeutic agent to maintain efficacy through the antigen-binding domain while reducing molecular size (from ~150 kDa to ~25-30 kDa) to improve penetration through biological barriers such as the blood-brain barrier and cellular uptake via transcytosis pathways.

Inventive Principle:

Principle #1Segmentation

2Speed

If an scFv is used to reduce molecular size and improve barrier penetration, then transcytosis and cellular uptake are enhanced, but circulation time and stability are reduced

Engineering Contradiction:

Improvetranscytosis rateVSAvoidcirculation half-life

Core Design Contradiction:

SpeedVSDuration of action of stationary object

Solution Approach 1:

Transferrin or its N-methyl lobe is used as an intermediary molecule that binds to the scFv. This conjugate utilizes the transferrin receptor-mediated endocytosis pathway, which is highly efficient for cellular uptake and transcytosis. The transferrin component facilitates rapid cellular internalization while the scFv maintains target specificity, thereby enhancing transcytosis rate without completely sacrificing circulation properties.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If transferrin is conjugated to scFv to enhance cellular uptake, then transcytosis is improved, but molecular weight and complexity increase

Engineering Contradiction:

Improvecellular uptake efficiencyVSAvoidconjugate structure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

Instead of conjugating the entire transferrin molecule (698 amino acids), only the essential N-methyl lobe (residues 22-350) is used. This extracted portion contains the critical iron-binding and receptor-interaction domains necessary for cellular uptake, while removing unnecessary portions that would increase molecular weight and structural complexity. This selective extraction maintains high transcytosis efficiency with a more streamlined conjugate structure.

Inventive Principle:

Principle #2Taking out (Extraction)

4Object-affected harmful factors

If cleavable linkers are incorporated for targeted release, then off-target effects are reduced, but manufacturing complexity and process difficulty increase

Engineering Contradiction:

Improveoff-target effectsVSAvoidrecombinant production

Core Design Contradiction:

Object-affected harmful factorsVSEase of manufacture

Solution Approach 1:

Cleavable linkers are incorporated into the scFv-transferrin conjugate that respond to specific physiological parameters such as pH changes or enzymatic conditions in the target cellular environment. These linkers remain stable during manufacturing and circulation but undergo controlled cleavage under specific in vivo conditions (e.g., acidic pH in endosomes or presence of specific proteases), enabling targeted release of the therapeutic agent at the destination while minimizing off-target effects. The modular nature of these linkers allows for relatively straightforward incorporation into the recombinant production process.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The scFv-conjugate achieves enhanced delivery across biological barriers, reduces off-target effects, and prolongs circulation time, ensuring effective targeting and therapeutic action in target cells.

Implementation Method 1

A single-chain variable fragment (scFv) is designed to bind with the N-methyl lobe of transferrin, utilizing transferrin receptor-mediated endocytosis to enhance cellular uptake

Methodology Applied

Scientific EffectTransferrin receptor-mediated endocytosis:

Data Source

PatentUS20260055170A1Single-chain romosozumab antibody-transferrin fusion protein for enhanced efficacy and indications

Publication Date: 2026.02.26 RNA THERAPEUTICS INC

AI summary

The efficacy and indication of romosozumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.